Taysha Gene Therapies, Inc.

TSHASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1806310

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	$15.5M	$2.5M	$2.5M	—	—
Research and Development Expense	$56.8M	$91.2M	$131.9M	$31.9M	$987.0K
Operating Expenses	$87.9M	$164.9M	$173.3M	$43.0M	$1.1M
Operating Income (Loss)	-$72.4M	-$162.4M	-$173.3M	-$43.0M	-$1.1M
Interest Expense	—	$3.8M	$1.4M	$28.0K	$28.0K
Nonoperating Income (Expense)	-$39.1M	-$3.6M	-$1.3M	-$17.0M	-$17.0M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$172.7M	$126.3M	$214.0M	$258.9M	$15.0K
Assets, Current	$149.9M	$96.4M	$159.6M	$257.9M	$15.0K
Cash and Cash Equivalents, at Carrying Value	$143.9M	$87.9M	$149.1M	$251.3M	$251.3M
Liabilities	$97.8M	$125.3M	$118.6M	$7.6M	$150.0K
Liabilities, Current	$36.8M	$62.8M	$51.7M	$7.1M	$150.0K
Long-term Debt	—	—	$38.0M	$37.2M	—
Accounts Payable, Current	$6.4M	$10.9M	$21.8M	$2.0M	$2.0M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$73.0M	-$88.4M	-$117.0M	-$30.7M	$0.00
Net Cash Provided by (Used in) Investing Activities	-$7.4M	-$24.9M	-$21.6M	-$9.1M	$0.00
Net Cash Provided by (Used in) Financing Activities	$136.4M	$52.1M	$39.1M	$291.1M	$0.00
Payments to Acquire Property, Plant, and Equipment	$3.9M	$20.6M	$15.3M	$82.0K	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)